CUMULATIVE SUPPLEMENT 6
JUNE 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 6

June 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 6
JUNE 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)
ROBERTS LABORATORIES INC ROBERTS LABS	SHIRE PHARMACEUTICAL DEVELOPMENT INC SHIRE PHARM
ROBERTS PHARMACEUTICAL CORP ROBERTS PHARM	SHIRE PHARMACEUTICAL DEVELOPMENT INC SHIRE PHARM

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
DRUG PRODUCTS LISTED	10360	10372	10155	
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)	302 (3.0%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	2	6	3	
NUMBER OF APPLICANTS	594	582	579	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone tablets were reviewed in the Drug Efficacy Study Implementation program. FDA published a Federal Register notice on August 15, 1974 (39 FR 29396) finding metaxalone tablets to be effective in the treatment of discomfort associated with acute, painful musculo-skeletal conditions. The Federal Register notice did not require the conduct of a bioavailability/bioequivalence study as a condition of marketing.

On March 6, 2001, URL Mutual Pharmaceutical Co. Inc submitted a citizen petition (Docket No. 01P-0117/CP1) asking FDA to reclassify the drug product metaxalone tablets from one not presenting bioequivalence problems to one that requires an in vivo demonstration of bioequivalence as a condition of approval for an ANDA. To support these assertions, the petition included results of two in vivo bioequivalence fasting studies and three separate in vitro dissolution tests. After a careful review of the data submitted by Mutual, the agency agreed that the firm has demonstrated a lack of correlation between in vitro dissolution and in vivo bioequivalence data of oral metaxalone tablets in two bioequivalence studies. The failure of both Mutual formulations to meet the 90% confidence intervals further supports the lack of in vitro/in vivo correlations.

Therefore, in accordance with our policy as enunciated in Section 1.9 of the Introduction to the 21st Edition of the Orange Book, we are providing a 60 day period in which interested parties may submit comments. The closing date for the comments will be November 30, 2001. The comments should be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. These comments should include scientific data either supporting or disagreeing with our proposal to change the therapeutic equivalence category for metaxalone tablets from a "non bioproblem" to a "bioproblem" drug.

		ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE						
		@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC	
		@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC	
		ACETAMINOPHEN; BUTALBITAL						
		CAPSULE; ORAL						
		TRIAPRIN						
		@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP	
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE						
		CAPSULE; ORAL						
		ANOQUAN						
		@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP	
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE						
		CAPSULE; ORAL						
		BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE						
	AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA	
		FIORICET W/ CODEINE						
	AB +	NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG	
		ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE						
		TABLET; ORAL						
		ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE						
		+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA	
		ACETAMINOPHEN; CODEINE PHOSPHATE						
		TABLET; ORAL						
		ACETAMINOPHEN AND CODEINE PHOSPHATE						
	AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA	
	AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA	
	AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA	
		CAPITAL WITH CODEINE						
		@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP	
		ACETAMINOPHEN; HYDROCODONE BITARTRATE						
>D>		ELIXIR; ORAL						
>D>		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
>D>	AA +	MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR	
>D>			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR	
>D>	+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR	
>D>	AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR	
>A>		SOLUTION; ORAL						
>A>		HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
>A>	AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001	JUN	NEWA	
>A>	AA +	MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR	
>A>			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR	
>A>	+		500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR	
>A>	AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR	
		TABLET; ORAL						
		+ WATSON LABS	750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA	
		LORTAB						

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

LORTAB

AA	+	WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN
		NORCO						
AA		WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@	HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
	@		650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
AB		MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
AB		VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR

AP		GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

>A>	AB		ARMSTRONG PHARMS	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN
>D>	AB		CELLTECH MFG	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

VENTOLIN HFA

	+		GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA

SOLUTION; INHALATION

ACCUNEB

	+		DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA
	+			EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA

ALBUTEROL SULFATE

>A>	AN		NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA
	AN		ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA

TABLET; ORAL

VENTOLIN

>D>	AB		GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
>A>		@		EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
>D>	AB			EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC
>A>		@		EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

	+		DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB			PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN

AB +		300MG	N16084 002	JAN 14, 1974	MAY	CAHN
	ALMOTRIPTAN MALATE					
	TABLET; ORAL					
	AXERT					
	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
	+	EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA
	AMIKACIN SULFATE					
	INJECTABLE; INJECTION					
	AMIKACIN SULFATE					
	@ ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
	@ ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC
	AMINOCAPROIC ACID					
	TABLET; ORAL					
	AMICAR					
AB +	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG
	AMINOCAPROIC					
AB	MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA
	AMIODARONE HYDROCHLORIDE					
	TABLET; ORAL					
	AMIODARONE HCL					
AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA
	AMOXICILLIN					
	CAPSULE; ORAL					
	AMOXICILLIN					
	@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
	@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP
	@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
	@	500MG	N62067 002	AUG 14, 1980	APR	DISC
	@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC
	@	500MG	N63031 001	FEB 28, 1989	APR	DISC
	TRIMOX					
	@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC
	@	500MG	N63099 002	MAR 20, 1992	APR	DISC
	WYMOX					
	@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC
	@	500MG	N62120 002	APR 28, 1978	APR	DISC
	FOR SUSPENSION; ORAL					
	TRIMOX					
	@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC
	@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC
	@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC

	AMOXICILLIN; CLAVULANATE POTASSIUM						
	FOR SUSPENSION; ORAL						
>A>	AUGMENTIN ES-600						
>A>	+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA	
	AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
	TABLET; ORAL						
	ADDERALL 7.5						
	SHIRE PHARM	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC	
	AMPHOTERICIN B						
	INJECTABLE; INJECTION						
	AMPHOTERICIN B						
	@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
	INJECTABLE, LIPID COMPLEX; INJECTION						
	AMPHOTEC						
+	INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+		100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	
	AMPICILLIN SODIUM						
	INJECTABLE; INJECTION						
	AMPICILLIN SODIUM						
	@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC	
	@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC	
	@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC	
	@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC	
	@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC	
	@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC	
	@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC	
	@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC	
	@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC	
	@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC	
	@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC	
	@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC	
	OMNIPEN-N						
	@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC	
	@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC	
	@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC

FOR SUSPENSION; ORAL

@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC

TOTACILLIN

@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN

@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+	SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/V IAL;0.14MG/VIAL;17MG/VIAL; 1MG/VIAL;1.4MG/VIAL;1.2MG/ VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/V IAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V IAL	N18920 001	SEP 21, 2000	FEB	NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE
TABLET; ORAL
INVAGESIC
AB GENEVA PHARMS TECH 385MG;30MG;25MG N74817 001 NOV 27, 1996 JAN CAHN
INVAGESIC FORTE
AB GENEVA PHARMS TECH 770MG;60MG;50MG N74817 002 NOV 27, 1996 JAN CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
@ EON 389MG;32.4MG;65MG N80044 002 SEP 16, 1983 MAY DISC
PROPOXYPHENE COMPOUND-65
@ GENEVA PHARMS 389MG;32.4MG;65MG N83101 002 JUN 24, 1985 MAY DISC

ATORVASTATIN CALCIUM
TABLET; ORAL
LIPITOR
PFIZER EQ 10MG BASE N20702 001 DEC 17, 1996 MAR CAHN
EQ 20MG BASE N20702 002 DEC 17, 1996 MAR CAHN
EQ 40MG BASE N20702 003 DEC 17, 1996 MAR CAHN
+ EQ 80MG BASE N20702 004 APR 07, 2000 MAR CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE
@ INWOOD LABS 0.025MG;2.5MG N85509 001 MAR 09, 1978 FEB WDRP
@ R AND S PHARMA 0.025MG;2.5MG N85035 001 JUL 05, 1977 MAY DISC
DIPHENOXYLATE HCL W/ ATROPINE SULFATE
@ PVT FORM 0.025MG;2.5MG N85766 001 DEC 22, 1978 MAY DISC

AURANOFIN
CAPSULE; ORAL
RIDAURA
+ PROMETHEUS LABS 3MG N18689 001 MAY 24, 1985 MAY CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN
@ PROMETHEUS LABS 25MG N16324 002 MAR 21, 1980 MAY CAHN
AB + 50MG N16324 001 MAR 20, 1968 MAY CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK
@ PFIZER EQ 1GM BASE;EQ 100MG BASE N50762 001 DEC 18, 1998 MAY DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX
@ PHARMA TEK 500,000 UNITS/BOT N61737 001 APR 26, 1973 MAY DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN

		@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
EMETE-CON

	+	PFIZER	EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN

BETAMETHASONE DIPROPIONATE
CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

		@ CLAY PARK	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

>A>	AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001	JUN	NEWA
	AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA

LOTRISONE

	AB	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG

BETAXOLOL HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
BETAXOLOL HCL

	AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA

BETHANECHOL CHLORIDE
TABLET; ORAL
DUVOID

>D>		@ ROBERTS LABS	10MG	N86262 001	MAR 22, 1978	JUN	CAHN
>D>		@	25MG	N86263 001	MAR 22, 1978	JUN	CAHN
>D>		@	50MG	N85882 003	MAR 22, 1978	JUN	CAHN
>A>		@ WELLSPRING PHARM	10MG	N86262 001	MAR 22, 1978	JUN	CAHN
>A>		@	25MG	N86263 001	MAR 22, 1978	JUN	CAHN
>A>		@	50MG	N85882 003	MAR 22, 1978	JUN	CAHN

BIMATOPROST
SOLUTION/DROPS; OPHTHALMIC
LUMIGAN

	+	ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE
TABLET, CHEWABLE, TABLET, CAPSULE; ORAL
HELIDAC

>D>	+	PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	JUN	DISC
>A>	+		262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	JUN	DISC
	+		262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC

BISOPROLOL FUMARATE
TABLET; ORAL
BISOPROLOL FUMARATE

>A>	AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
>A>	AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

>D>	AB	APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
>A>		@	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
>D>	AB		5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
>A>		@	5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
>D>	AB		10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
>A>		@	10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
	AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
	AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
	AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

@	ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC

ALPHAGAN P

+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; SPINAL
MARCAINE

>A>	AP	+	ABBOTT	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN
>D>	AP	+	SANOFI SYNTHELABO	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR

		GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
			100MG	N20358 002	OCT 04, 1996	APR	CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPAR

AB	BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB		10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB		15MG	N18731 003	APR 22, 1996	MAR	NEWA
>D>	+	30MG	N18731 004	APR 22, 1996	JUN	CFTG
>A>	AB +	30MG	N18731 004	APR 22, 1996	JUN	CFTG

BUSPIRONE HCL

AB	DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB		10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB	MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
>A>	AB	MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA
	AB	PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

		BUTABARBITAL SODIUM						
		TABLET; ORAL						
		BUTISOL SODIUM						
		+ WALLACE LABS	15MG	N00793	002	JUN 05, 1939	MAY	CTEC
		SODIUM BUTABARBITAL						
		@ LANNETT	15MG	N85849	001	AUG 21, 1978	MAY	DISC
		@	30MG	N85866	001	JUL 20, 1978	MAY	DISC
		CALCITONIN, SALMON						
		INJECTABLE; INJECTION						
>D>		CALCITONIN-SALMON						
>D>	AP	ASTRAZENECA	200 IU/ML	N73690	001	APR 14, 1995	JUN	DISC
>A>		@	200 IU/ML	N73690	001	APR 14, 1995	JUN	DISC
		CALCIUM ACETATE						
		CAPSULE; ORAL						
		PHOSLO						
		BRAINTREE	EQ 84.5MG CALCIUM	N21160	001	APR 02, 2001	APR	NEWA
		+	EQ 169MG CALCIUM	N21160	002	APR 02, 2001	APR	NEWA
		CAPTOPRIL						
		TABLET; ORAL						
		CAPTOPRIL						
	AB	GENEVA PHARMS TECH	12.5MG	N74481	001	FEB 13, 1996	JAN	CAHN
	AB		25MG	N74481	002	FEB 13, 1996	JAN	CAHN
	AB		50MG	N74481	003	FEB 13, 1996	JAN	CAHN
	AB		100MG	N74481	004	FEB 13, 1996	JAN	CAHN
		CARBACHOL						
		SOLUTION; INTRAOCULAR						
		CARBASTAT						
	AT	NOVARTIS	0.01%	N73677	001	APR 28, 1995	FEB	CAHN
		CARBIDOPA; LEVODOPA						
		TABLET; ORAL						
		CARBIDOPA AND LEVODOPA						
		@ SCS	10MG;100MG	N74080	001	MAR 25, 1994	FEB	WDRP
		@	25MG;100MG	N74080	002	MAR 25, 1994	FEB	WDRP
		@	25MG;250MG	N74080	003	MAR 25, 1994	FEB	WDRP
		CARISOPRODOL						
		TABLET; ORAL						
		CARISOPRODOL						
>A>	AA	ABLE	350MG	N40421	001	JUN 21, 2001	JUN	NEWA
		CASPOFUNGIN ACETATE						
		INJECTABLE; IV (INFUSION)						
		CANCIDAS						
		+ MERCK RES	50MG/VIAL	N21227	001	JAN 26, 2001	JAN	NEWA
		+	70MG/VIAL	N21227	002	JAN 26, 2001	JAN	NEWA

CEFACLOR
CAPSULE; ORAL
CECLOR

>A>	AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
>A>	AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN
>D>	AB	LILLY	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
>D>	AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

		@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
		@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
		@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

		LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC
	AB +		EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG

CEFACLOR

	AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL

		@ ZENITH GOLDLINE	EQ 1GM BASE	N62774 001	APR 08, 1987	MAY	DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL

		@ LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985	MAY	DISC
		@	EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985	MAY	DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM

		@ TEVA	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC
		@	EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC
		@	EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC

KEFZOL

		@ LILLY	EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985	MAY	DISC
		@	EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985	MAY	DISC

CEFONICID SODIUM
INJECTABLE; INJECTION
MONOCID

		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC

CEFOPERAZONE SODIUM
INJECTABLE; INJECTION
CEFOBID

		@ PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995	MAY	DISC
		@	EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995	MAY	DISC

CEFORANIDE
INJECTABLE; INJECTION
PRECEF

	@ APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC
	@	1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC
	@	2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC
	@	10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC
	@	20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC

CEFTAZIDIME
INJECTABLE; INJECTION
TAZICEF

AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN

TAZIDIME IN PLASTIC CONTAINER

	@ LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
	@	2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC

CEFUROXIME SODIUM
INJECTABLE; IM-IV
CEFUROXIME

AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA
AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR

CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR

ZINACEF

AB +	GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR

INJECTABLE; INJECTION
CEFUROXIME

AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
+		EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA

KEFUROX IN PLASTIC CONTAINER

	@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC

INJECTABLE; INTRAVENOUS

	@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC

CEPHALEXIN
CAPSULE; ORAL
CEPHALEXIN

	@ TEVA	EQ 500MG BASE	N62823 001	FEB 05, 1988	MAY	DISC

KEFLEX

>A>	AB	CEPH INTL	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN
>A>	AB		EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN
>D>	AB	LILLY	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN

>D>	AB	EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN
	FOR SUSPENSION; ORAL					
	CEPHALEXIN					
	@ BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987	MAY	DISC
	KEFLEX					
>A>	+ CEPH INTL	EQ 100MG BASE/ML	N62117 001	MAR 27, 1978	JUN	CAHN
>A>	AB	EQ 125MG BASE/5ML	N62117 002	MAR 27, 1978	JUN	CAHN
>A>	AB +	EQ 250MG BASE/5ML	N62117 003	MAR 27, 1978	JUN	CAHN
>D>	+ LILLY	EQ 100MG BASE/ML	N62117 001	MAR 27, 1978	JUN	CAHN
>D>	AB	EQ 125MG BASE/5ML	N62117 002	MAR 27, 1978	JUN	CAHN
>D>	AB +	EQ 250MG BASE/5ML	N62117 003	MAR 27, 1978	JUN	CAHN
	CEPHALOTHIN SODIUM					
	INJECTABLE; INJECTION					
	KEFLIN IN PLASTIC CONTAINER					
	@ LILLY	EQ 1GM BASE/VIAL	N62549 001	SEP 10, 1985	APR	DISC
	@	EQ 2GM BASE/VIAL	N62549 002	SEP 10, 1985	APR	DISC
	CHLORAMPHENICOL					
	CAPSULE; ORAL					
	CHLORAMPHENICOL					
	@ ZENITH GOLDLINE	250MG	N62247 001	APR 28, 1980	MAY	DISC
	CHLOROMYCETIN					
	@ PARKEDALE	50MG	N60591 001	DEC 08, 1950	MAY	DISC
	@	100MG	N60591 003	DEC 08, 1950	MAY	DISC
	@	250MG	N60591 002	DEC 08, 1950	MAY	DISC
	MYCHEL					
	+ ARMENPHARM	250MG	N60851 001	JUN 20, 1967	MAY	CRLD
	SOLUTION/DROPS; OPHTHALMIC					
	CHLORAMPHENICOL					
	@ AKORN	0.5%	N62042 001	AUG 31, 1981	FEB	WDRP
	@ ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC
	CHLOROPTIC					
	+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC
	CHLORDIAZEPOXIDE HYDROCHLORIDE					
	CAPSULE; ORAL					
	CHLORDIAZACHEL					
	@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
	@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
	@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
	CHLORDIAZEPOXIDE HCL					
	@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
	@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
	@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
	@ GENEVA PHARMS	10MG	N84041 001	JUN 15, 1976	MAY	DISC
	@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
	@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
	CHLOROTHIAZIDE					
	TABLET; ORAL					
	CHLOROTHIAZIDE					
	@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC

		@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC
		CHLORPHENIRAMINE MALEATE					
		TABLET; ORAL					
		CHLORPHENIRAMINE MALEATE					
		@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
	AA +	ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
		@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
		@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP
		CHLORPROMAZINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		CHLORPROMAZINE HCL					
		@ STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC
		CHLORZOXAZONE					
		TABLET; ORAL					
		CHLORZOXAZONE					
		@ DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC
		CIMETIDINE					
		TABLET; ORAL					
		CIMETIDINE					
	AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
	AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
	AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
	AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN
		CLINDAMYCIN HYDROCHLORIDE					
		CAPSULE; ORAL					
		CLEOCIN HCL					
	AB +	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG
		CLINDAMYCIN HCL					
	AB	RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
	AB		EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA
		CLINDAMYCIN PHOSPHATE					
		INJECTABLE; INJECTION					
		CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	+	PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG
>A>	AP +		EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG
		CLINDAMYCIN PHOSPHATE					
		@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
		@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
		@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
		@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
		@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC
		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER					
>A>	AP	ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
>A>	AP		EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
>A>	AP		EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA
		SOLUTION; TOPICAL					

CLINDAMYCIN PHOSPHATE
SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

	@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
	@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE
CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1	STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE; ORAL
ANAFRANIL

>D>	AB	NOVARTIS	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
>D>	AB +		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
>D>	AB		75MG	N19906 003	DEC 29, 1989	JUN	CAHN
>A>	AB	TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
>A>	AB +		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
>A>	AB		75MG	N19906 003	DEC 29, 1989	JUN	CAHN

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
@	15MG	N71779 001	JUL 14, 1987	JAN	DISC

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

CYCLACILLIN
TABLET; ORAL
CYCLACILLIN

@ TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC
@	500MG	N62895 002	AUG 04, 1988	MAY	DISC

DACARBAZINE
INJECTABLE; INJECTION
DACARBAZINE

>A>	AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001	JUN	NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL

		ORETICYL 25					
		@ ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC
		ORETICYL 50					
		@ ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC
		ORETICYL FORTE					
		@ ABBOTT	0.25MG;25MG	N12148 002	DEC 14, 1959	MAR	DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE

	AB	ALTANA	0.05%	N75751 001	MAR 12, 2001	MAR	NEWA

DEXAMETHASONE
TABLET; ORAL
DEXAMETHASONE

		@ DANBURY PHARMA	0.75MG	N80968 001	MAY 03, 1973	MAY	DISC

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

		@ DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
		@ GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC

OINTMENT; OPHTHALMIC
DECADRON

		@ MERCK	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC
		MAXIDEX					
	+	ALCON	EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC

SOLUTION/DROPS; OTIC
DEXAMETHASONE SODIUM PHOSPHATE

		@ AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SOLUTION/DROPS; OPHTHALMIC
NEODECADRON

	+	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

		@ ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
DEXACIDIN

	AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN

	@	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC	
	SUSPENSION/DROPS; OPHTHALMIC						
AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN	
	DEXTROAMPHETAMINE SULFATE						
	TABLET; ORAL						
	DEXTROAMPHETAMINE SULFATE						
AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA	
AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA	
	DEXTROSTAT						
AA +	SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG	
	DICLOFENAC POTASSIUM						
	TABLET; ORAL						
	DICLOFENAC POTASSIUM						
AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA	
	DICLOFENAC SODIUM						
	GEL; TOPICAL						
	SOLARAZE						
+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN	
	DICLOXACILLIN SODIUM						
	CAPSULE; ORAL						
	DYCILL						
	@ SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC	
	@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC	
	DICYCLOMINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	DICYCLOMINE HCL						
	@ HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC	
	DILTIAZEM HYDROCHLORIDE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	DILTIAZEM HCL						
AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC	
	DIPHENHYDRAMINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	DIPHENHYDRAMINE HCL						
	@ CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC	
	@ NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP	
	@	50MG	N86544 001	FEB 08, 1979	FEB	WDRP	
	DISULFIRAM						
	TABLET; ORAL						
	ANTABUSE						
	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN	
+		500MG	N88483 001	DEC 08, 1983	JAN	CAHN	
	@ SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN	

		@	500MG	N07883 002	JUN 01, 1953	MAR	CAHN
		DOXAZOSIN MESYLATE						
		TABLET; ORAL						
		DOXAZOSIN MESYLATE						
>A>	AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA
>A>	AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
>A>	AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
>A>	AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
	AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
	AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
	AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
	AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA
		DOXYCYCLINE						
		FOR SUSPENSION; ORAL						
		DOXYCHEL						
		@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP
		VIBRAMYCIN						
	+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC
		DOXYCYCLINE HYCLATE						
		CAPSULE; ORAL						
		DOXY-LEMMON						
		@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
		@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC
		DOXYCYCLINE HYCLATE						
		@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
		@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
>A>	AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
		@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
>A>	AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
		@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC
>D>	AB	HOUBA	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
>D>	AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
		CAPSULE, COATED PELLETS; ORAL						
		@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC
		INJECTABLE; INJECTION						
		DOXYCHEL HYCLATE						
		@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP
		DOXYCYCLINE						
		@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC
		@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC
		@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC
		@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC
		DOXYCYCLINE HYCLATE						
		@ LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC
		@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC
		TABLET; ORAL						
		DOXY-LEMMON						
		@ TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC
		DOXYCYCLINE HYCLATE						
>A>	AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN

>A>	AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN
		@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC
>D>	AB	HOUBA	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN
>D>	AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN
		DOXYCYCLINE HYLATE					
>A>		@ HALSEY	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN
>D>		@ HOUBA	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN
		PERIOSTAT					
	+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA
		DROSPIRENONE; ETHINYL ESTRADIOL					
		TABLET; ORAL-28					
		YASMIN					
	+	BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA
		ENALAPRIL MALEATE					
		TABLET; ORAL					
		ENALAPRIL MALEATE					
	AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA
	AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA
	AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA
	AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA
	AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA
	AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA
	AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA
	AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA
		ENFLURANE					
		LIQUID; INHALATION					
		ENFLURANE					
	AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN
		ENOXAPARIN SODIUM					
		INJECTABLE; SUBCUTANEOUS					
		LOVENOX					
	+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
	+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
	+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
	+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
	+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
	+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
	+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
	+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN
		EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		DURANEST					
	+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
	+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
@ DENTSPLY PHARM 0.005MG/ML;0.5% N17751 004 AUG 30, 1976 APR CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCATON
@ PHARMATON 0.02MG/ML;2% N84728 001 AUG 17, 1983 FEB WDRP

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D
@ IMPAX LABS 50,000 IU N80951 001 JUL 13, 1973 FEB DISC

ERYTHROMYCIN
SOLUTION; TOPICAL
ERYTHROMYCIN
@ CLAY PARK 2% N63038 001 JAN 11, 1991 APR DISC
AT 2% N63038 001 JAN 11, 1991 MAY CMFD
TABLET, DELAYED RELEASE; ORAL
E-BASE
@ BARR 333MG N63028 001 MAY 15, 1990 APR DISC
ILOTYCIN
@ DISTA 250MG N61910 001 FEB 27, 1975 MAY DISC

ERYTHROMYCIN ESTOLATE
CAPSULE; ORAL
ERYTHROMYCIN ESTOLATE
+ BARR EQ 250MG BASE N62162 002 JUN 15, 1981 MAY CTEC
@ DANBURY PHARMA EQ 250MG BASE N62087 001 JUN 14, 1979 APR DISC
ILOSONE
@ LILLY EQ 125MG BASE N61897 001 JAN 06, 1975 MAY DISC
@ EQ 250MG BASE N61897 002 JAN 06, 1975 MAY DISC
FOR SUSPENSION; ORAL
@ DISTA EQ 125MG BASE/5ML N61893 001 JAN 06, 1975 MAY DISC
SUSPENSION/DROPS; ORAL
@ LILLY EQ 100MG BASE/ML N61894 003 JAN 07, 1975 APR DISC
TABLET; ORAL
@ LILLY EQ 500MG BASE N61896 001 JAN 03, 1975 APR DISC
TABLET, CHEWABLE; ORAL
@ DISTA EQ 125MG BASE N61895 001 JAN 03, 1975 MAY DISC
@ EQ 250MG BASE N61895 002 JAN 03, 1975 MAY DISC

ERYTHROMYCIN ETHYLSUCCINATE
TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
@ BARR EQ 400MG BASE N62256 001 APR 28, 1980 MAY DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
ERYTHROMYCIN STEARATE
@ BARR EQ 500MG BASE N63179 001 MAY 15, 1990 MAY DISC

	@ ZENITH GOLDLINE	EQ 250MG BASE	N61461	001	SEP 04, 1971	MAY	DISC
	@	EQ 500MG BASE	N61461	002	APR 11, 1980	MAY	DISC
	WYAMYCIN S						
	@ WYETH AYERST	EQ 250MG BASE	N61675	001	OCT 06, 1972	APR	DISC
	@	EQ 500MG BASE	N61675	002	JUL 13, 1973	APR	DISC
	ESOMEPRAZOLE MAGNESIUM						
	CAPSULE, DELAYED REL PELLETS; ORAL						
	NEXIUM						
+	ASTRAZENECA	EQ 20MG BASE	N21153	001	FEB 20, 2001	FEB	NEWA
+		EQ 40MG BASE	N21153	002	FEB 20, 2001	FEB	NEWA
	ESTRADIOL; NORETHINDRONE ACETATE						
	FILM, EXTENDED RELEASE; TRANSDERMAL						
	COMBIPATCH						
	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870	001	AUG 07, 1998	MAR	CAHN
+		0.05MG/24HR;0.25MG/24HR	N20870	002	AUG 07, 1998	MAR	CAHN
	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
	TABLET; ORAL-28						
	PREMPRO						
+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M G	N20527	001	NOV 17, 1995	JAN	CTNA
+		0.625MG;0.625MG;5MG;5MG	N20527	003	JAN 09, 1998	JAN	CTNA
	PREMPRO (PREMARIN;CYCRIN)						
+	WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5M G	N20303	001	DEC 30, 1994	JAN	CTNA
	ESTROPIPATE						
	TABLET; ORAL						
	ORTHO-EST						
AB	WOMEN FIRST HLTHCARE	0.75MG	N89567	001	FEB 27, 1991	JAN	CAHN
AB		1.5MG	N89582	001	JUL 17, 1991	JAN	CAHN
	ETHINYL ESTRADIOL; LEVONORGESTREL						
	TABLET; ORAL-21						
	ALESSE						
AB +	WYETH AYERST	0.02MG;0.1MG	N20683	001	MAR 27, 1997	APR	CTEC
	AVIANE-21						
AB	DURAMED	0.02MG;0.1MG	N75796	002	APR 30, 2001	APR	NEWA
	TABLET; ORAL-28						
	ALESSE						
AB	WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	APR	CTEC
	AVIANE-28						
AB	DURAMED	0.02MG;0.1MG	N75796	001	APR 30, 2001	APR	NEWA
	ETHINYL ESTRADIOL; NORETHINDRONE ACETATE						
	TABLET; ORAL-28						
	LOESTRIN FE 1.5/30						
AB +	PARKE DAVIS	0.03MG;1.5MG	N17355	001	APR 30, 1973	FEB	CFTG
	LOESTRIN FE 1/20						
AB +	PARKE DAVIS	0.02MG;1MG	N17354	001	APR 30, 1973	FEB	CFTG
	MICROGESTIN FE 1.5/30						

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL-28
MICROGESTIN FE 1.5/30

AB	WATSON LABS	0.03MG;1.5MG	N75548 001	FEB 05, 2001	FEB	NEWA
	MICROGESTIN FE 1/20					
AB	WATSON LABS	0.02MG;1MG	N75647 001	FEB 05, 2001	FEB	NEWA

ETHOSUXIMIDE
SYRUP; ORAL
ZARONTIN

AA	+ PARKE DAVIS	250MG/5ML	N80258 001	FEB 13, 1974	JAN	CRLD

ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

	@ DENTSPLY PHARM	0.5%	N17751 003	AUG 30, 1976	APR	CAHN
	+	1%	N17751 005	AUG 30, 1976	APR	CAHN

ETODOLAC
TABLET, EXTENDED RELEASE; ORAL
ETODOLAC

AB	TEVA	400MG	N75665 003	FEB 05, 2001	FEB	NEWA

ETOPOSIDE PHOSPHATE
INJECTABLE; INJECTION
ETOPOPHOS PRESERVATIVE FREE

>D>	+ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998	JUN	DISC
>A>	@	EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998	JUN	DISC
>A>	@	EQ 1GM BASE/VIAL	N20906 002	FEB 27, 1998	JUN	NEWA

FAMCICLOVIR
TABLET; ORAL
FAMVIR
NOVARTIS

		125MG	N20363 003	DEC 11, 1995	JAN	CAHN
		250MG	N20363 001	APR 26, 1996	JAN	CAHN
	+	500MG	N20363 002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE
INJECTABLE; INJECTION
FAMOTIDINE

AP	AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75707 001	APR 16, 2001	APR	NEWA
	@	10MG/ML	N75707 001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA
AP		10MG/ML	N75684 001	APR 16, 2001	APR	NEWA
AP	ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA
	FAMOTIDINE PRESERVATIVE FREE					
AP	AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA
AP	APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA
	@	10MG/ML	N75708 001	APR 16, 2001	MAY	DISC
AP	BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA
AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA

AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA
AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA
	FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER					
AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA
	PEPCID					
AP +	MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG
	PEPCID PRESERVATIVE FREE					
AP +	MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG
	PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER					
AP +	MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG
	TABLET; ORAL					
	FAMOTIDINE					
AB	CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
AB		40MG	N75805 002	APR 16, 2001	APR	NEWA
AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
AB		40MG	N75062 001	APR 16, 2001	APR	NEWA
AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
AB		40MG	N75718 002	APR 16, 2001	APR	NEWA
AB	EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
AB		40MG	N75793 002	APR 16, 2001	APR	NEWA
AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
AB		40MG	N75302 002	APR 16, 2001	APR	NEWA
AB	GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
AB		40MG	N75457 002	APR 18, 2001	APR	NEWA
AB	INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
AB		40MG	N75607 002	MAY 10, 2001	MAY	NEWA
AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
AB		40MG	N75704 002	APR 16, 2001	APR	NEWA
AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
AB		40MG	N75311 002	APR 16, 2001	APR	NEWA
AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
AB		40MG	N75786 002	APR 16, 2001	APR	NEWA
AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
AB		40MG	N75511 002	APR 16, 2001	APR	NEWA
	PEPCID					
AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
AB +		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL						
DURAGESIC						
ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
	1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
	2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE

INJECTABLE; INJECTION						
FENTANYL CITRATE PRESERVATIVE FREE						
@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP	AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

	@ CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC
	@	0.025%	N86811 001	MAR 04, 1982	APR	DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

	@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB	NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC

	+ DERMIK LABS	0.5%	N20985 001	OCT 27, 2000	MAY	CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS; ORAL
PROZAC WEEKLY

	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA

FLURBIPROFEN
TABLET; ORAL
FLURBIPROFEN

AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA
AB		100MG	N75058 002	APR 27, 2001	APR	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA

AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL
\+ NOVARTIS — 0.012MG/INH — N20831 001 FEB 16, 2001 FEB NEWA

GABAPENTIN
CAPSULE; ORAL
NEURONTIN
PFIZER

		100MG	N20235 001	DEC 30, 1993	MAR	CAHN
		300MG	N20235 002	DEC 30, 1993	MAR	CAHN
+		400MG	N20235 003	DEC 30, 1993	MAR	CAHN

GALANTAMINE HYDROBROMIDE

>A>	SOLUTION; ORAL					
>A>	REMINYL					
>A>	\+ JANSSEN	4MG/ML	N21224 001	JUN 22, 2001	JUN	NEWA
	TABLET; ORAL					
	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
	\+	EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA

GEMFIBROZIL
TABLET; ORAL
GEMFIBROZIL
AB GENEVA PHARMS TECH — 600MG — N74615 001 SEP 29, 1995 JAN CAHN

GENTAMICIN SULFATE

	CREAM; TOPICAL					
	GENTAMICIN SULFATE					
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC
	INJECTABLE; INJECTION					
	@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC
	@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC
	@ STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC
	@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC
	U-GENCIN					
	@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
	@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP
	INJECTABLE; INTRATHECAL					
	GARAMYCIN					
	@ SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC
	OINTMENT; OPHTHALMIC					
	GENTACIDIN					
AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
	@	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC
	OINTMENT; TOPICAL					

		GENTAMICIN SULFATE						
		OINTMENT; TOPICAL						
		GENTAMICIN SULFATE						
		@ BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC	
		SOLUTION/DROPS; OPHTHALMIC						
	AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN	
		GENTAMICIN SULFATE						
		@ ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC	
		GLIPIZIDE						
		TABLET; ORAL						
		GLIPIZIDE						
	AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN	
	AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN	
>A>	AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA	
>A>	AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA	
		GLYCOPYRROLATE						
		INJECTABLE; INJECTION						
		GLYCOPYRROLATE						
		@ GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC	
		GRANISETRON HYDROCHLORIDE						
>A>		SOLUTION; ORAL						
>A>		KYTRIL						
>A>		+ ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA	
		GRISEOFULVIN, MICROCRYSTALLINE						
		SUSPENSION; ORAL						
		GRIFULVIN V						
		+ J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD	
		@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC	
		GRISEOFULVIN, ULTRAMICROCRYSTALLINE						
		TABLET; ORAL						
		GRISACTIN ULTRA						
		@ WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC	
		@	250MG	N62178 002	MAR 13, 1980	APR	DISC	
		ULTRAGRIS-165						
		@ SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC	
		ULTRAGRIS-330						
		@ SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC	
		HALOPERIDOL LACTATE						
		INJECTABLE; INJECTION						
		HALOPERIDOL						
>D>	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	JUN	CTNA	
>A>	AP		EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	JUN	CTNA	
>A>	AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	JUN 18, 2001	JUN	NEWA	
		HALOPERIDOL LACTATE						
	AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	MAR	NEWA	

HALOTHANE
LIQUID; INHALATION
HALOTHANE
@ BH 99.99% N84977 001 JUL 14, 1976 JAN DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT 10,000 UNITS/ML N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY 1,000 UNITS/ML N86129 001 FEB 22, 1980 FEB WDRP

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL
AP AM PHARM PARTNERS 20MG/ML N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 25MG;15MG;0.1MG N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 50MG N83232 001 JAN 24, 1975 MAY DISC
@ HALSEY 25MG N83972 001 OCT 03, 1974 MAY DISC
@ 50MG N83972 002 OCT 03, 1974 MAY DISC
@ IMPAX LABS 25MG N84029 001 JUL 05, 1977 MAY DISC
@ 50MG N83607 002 JUN 06, 1977 MAY DISC
@ PHARMERAL 25MG N84325 001 JUN 24, 1976 MAY DISC
@ 50MG N84324 001 JUN 24, 1976 MAY DISC
@ WEST WARD 50MG N84878 001 JAN 31, 1977 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDRO-RESERP
@ ABC HOLDING 50MG;0.125MG N84714 002 JUN 29, 1982 MAY DISC
HYDROCHLOROTHIAZIDE W/ RESERPINE
@ DANBURY PHARMA 25MG;0.125MG N84466 001 JAN 07, 1977 MAY DISC
@ 50MG;0.125MG N84467 001 JAN 07, 1977 MAY DISC
RESERPINE AND HYDROCHLOROTHIAZIDE-50
@ WEST WARD 50MG;0.125MG N88189 001 MAY 10, 1984 FEB WDRP

HYDROCORTISONE
CREAM; TOPICAL
HC (HYDROCORTISONE)
@ C AND M PHARMA 0.5% N80482 003 MAR 20, 1973 FEB WDRP
@ 1% N80482 004 MAR 20, 1973 FEB WDRP
HYDROCORTISONE
@ TOPIDERM 1% N89273 001 FEB 17, 1989 FEB WDRP
PROCTOCORT

		HYDROCORTISONE						
		CREAM; TOPICAL						
		PROCTOCORT						
		@ MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC	
		LOTION; TOPICAL						
		BETA-HC						
		@ BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP	
		GLYCORT						
		@ HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP	
		HYDROCORTISONE						
		@ MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC	
		@	1%	N85282 002	FEB 26, 1987	MAY	DISC	
		OINTMENT; TOPICAL						
		HC (HYDROCORTISONE)						
		@ C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP	
		POWDER; FOR RX COMPOUNDING						
		H-CORT						
		@ TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP	
		SOLUTION; TOPICAL						
		TEXACORT						
>D>	AT +	BIOGLAN PHARMA	1%	N80425 001	DEC 22, 1971	JUN	CAHN	
>A>	AT +	SIRIUS LABS	1%	N80425 001	DEC 22, 1971	JUN	CAHN	
	+		2.5%	N81271 001	APR 17, 1992	MAY	CAHN	
		TABLET; ORAL						
		HYDROCORTISONE						
		@ LANNETT	20MG	N85070 001	MAY 07, 1976	MAY	DISC	
		HYDROCORTISONE ACETATE						>D>
		CREAM; TOPICAL						>D>
		MICORT-HC						>D>
		FERNDALE LABS	2.5%	N40396 001	FEB 27, 2001	FEB	NEWA	>A>
								>A>
								>A>
		HYDROCORTISONE ACETATE; NEOMYCIN SULFATE						
		OINTMENT; TOPICAL						
		NEO-CORTEF						
		@ PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N60751 002	MAY 18, 1965	APR	DISC	
		SUSPENSION/DROPS; OPHTHALMIC						>D>
		COR-OTICIN						>D>
		@ AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	OCT 26, 1968	FEB	WDRP	>D>
								>D>
		HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						>A>
		SOLUTION/DROPS; OTIC						>A>
		NEO-OTOSOL-HC						>A>
		@ ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	APR	DISC	>A>
		SUSPENSION/DROPS; OPHTHALMIC						
		CORTISPORIN						
	+	MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169 001	DEC 18, 1964	MAY	CTEC	
		NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
		@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	MAY	DISC	
		SUSPENSION/DROPS; OTIC						

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	APR	DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

@ STERIS	25MG/ML	N85778 001	OCT 05, 1979	MAY	DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ GENEVA PHARMS	EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
@	EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

IMATINIB MESYLATE

CAPSULE; ORAL

GLEEVEC

NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
+	100MG	N21335 002	MAY 10, 2001	MAY	NEWA

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

TOFRANIL

>D>	AB	NOVARTIS	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
>D>	AB		25MG	N87845 001	MAY 22, 1984	JUN	CAHN
>D>	AB	+	50MG	N87846 001	MAY 22, 1984	JUN	CAHN
>A>	AB	TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
>A>	AB		25MG	N87845 001	MAY 22, 1984	JUN	CAHN
>A>	AB	+	50MG	N87846 001	MAY 22, 1984	JUN	CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

TOFRANIL-PM

>D>		NOVARTIS	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
>D>			EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
>D>			EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
>D>		+	EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN
>A>		TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
>A>			EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
>A>			EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
>A>		+	EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

AB		GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB			2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN		ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA	
AN		NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA	
AN		WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA	

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

AN		MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN	

ISONIAZID
SYRUP; ORAL
ISONIAZID

	+	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC	
		@ MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC	

TABLET; ORAL

		@ HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC	

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

	+	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC	>A>

KANAMYCIN SULFATE
INJECTABLE; INJECTION
KANAMYCIN SULFATE

		@ LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC	>D>
		@	EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC	
		@	EQ 1GM BASE/3ML	N63025 001	JUL 31,.1992	APR	DISC	>D>
		@ STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC	>D>

KANTREX

	+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC	>A>
	+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC	>A>
	+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC	>D>

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

>A>	AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA	
>A>	AP		30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA	
		@ APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC	
		@	30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC	

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

		@ APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC	

TRANDATE

AP	+	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN	

		LAMOTRIGINE						
		TABLET, CHEWABLE; ORAL						
		LAMICTAL CD						
		GLAXO WELLCOME	2MG	N20764	004	SEP 08, 2000	MAR	NEWA
		LANSOPRAZOLE						
		FOR SUSPENSION, EXTENDED RELEASE; ORAL						
		PREVACID						
		TAP PHARM	15MG/PACKET	N21281	001	MAY 03, 2001	MAY	NEWA
		+	30MG/PACKET	N21281	002	MAY 03, 2001	MAY	NEWA
		LEUCOVORIN CALCIUM						
		INJECTABLE; INJECTION						
		LEUCOVORIN CALCIUM PRESERVATIVE FREE						
	AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338	001	JAN 31, 2001	JAN	NEWA
		LEVOCARNITINE						
		INJECTABLE; INJECTION						
		CARNITOR						
	AP +	SIGMA TAU	200MG/ML	N20182	001	DEC 16, 1992	MAR	CFTG
		LEVOCARNITINE						
	AP	BEDFORD	200MG/ML	N75567	001	MAR 29, 2001	MAR	NEWA
	AP	GENSIA SICOR PHARMS	200MG/ML	N75881	001	MAR 29, 2001	MAR	NEWA
>A>	AP	LUITPOLD	200MG/ML	N75861	001	JUN 22, 2001	JUN	NEWA
		LEVODOPA						
		CAPSULE; ORAL						
>D>		DOPAR						
		@ SHIRE LABS	250MG	N16913	001	JUN 04, 1970	MAY	DISC
		TABLET; ORAL						
>D>	BD	ROBERTS LABS	250MG	N16913	004	JUL 06, 1972	JUN	DISC
>D>	BD		500MG	N16913	005	JUL 06, 1972	JUN	DISC
>A>		@ SHIRE LABS	250MG	N16913	004	JUL 06, 1972	JUN	DISC
>A>		@	500MG	N16913	005	JUL 06, 1972	JUN	DISC
		LARODOPA						
>D>	BD	ROCHE	250MG	N16912	003	JUN 04, 1970	JUN	CRLD
>A>			250MG	N16912	003	JUN 04, 1970	JUN	CRLD
>D>	BD +		500MG	N16912	004	JUN 04, 1970	JUN	CRLD
>A>	+		500MG	N16912	004	JUN 04, 1970	JUN	CRLD
		LEVOTHYROXINE SODIUM						
		TABLET; ORAL						
		LEVOXYL						
	BX +	JONES PHARMA	0.025MG	N21301	001	MAY 25, 2001	MAY	NEWA
	BX		0.05MG	N21301	002	MAY 25, 2001	MAY	NEWA
	BX		0.075MG	N21301	003	MAY 25, 2001	MAY	NEWA
	BX		0.088MG	N21301	004	MAY 25, 2001	MAY	NEWA
	BX		0.1MG	N21301	005	MAY 25, 2001	MAY	NEWA
	BX		0.112MG	N21301	006	MAY 25, 2001	MAY	NEWA
	BX		0.125MG	N21301	007	MAY 25, 2001	MAY	NEWA
	BX		0.137MG	N21301	008	MAY 25, 2001	MAY	NEWA
	BX		0.15MG	N21301	009	MAY 25, 2001	MAY	NEWA

	BX		0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
	BX		0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
	BX		0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA
		UNITHROID					
	BX	STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC
	BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
	BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
	BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
	BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
	BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
	BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
	BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
	BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
	BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
	BX +		0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
		LIDOCAINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		LIDOCATON					
		@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
		LINCOMYCIN HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		LINCOCIN					
		+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
		LINCOMYCIN HCL					
		@ STERIS	EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
		LISINOPRIL					
		TABLET; ORAL					
		ZESTRIL					
	AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
		LITHIUM CARBONATE					
		CAPSULE; ORAL					
		ESKALITH					
>D>	AB +	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
>A>	AB		300MG	N16860 001	APR 06, 1970	JUN	CRLD
		LITHIUM CARBONATE					
>D>		ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
>A>	+		600MG	N17812 003	JAN 28, 1987	JUN	CRLD
		MECLIZINE HYDROCHLORIDE					
		TABLET; ORAL					
		MECLIZINE HCL					
		@ CHELSEA LABS	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC
		MEPERIDINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		MEPERIDINE HCL					
>D>	AP	ASTRAZENECA	50MG/ML	N89784 001	MAR 31, 1989	JUN	DISC
>A>		@	50MG/ML	N89784 001	MAR 31, 1989	JUN	DISC
>D>	AP		100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC

>A>		@	100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC	

MEPROBAMATE

TABLET; ORAL

AMOSENE

		@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP	

MEPROBAMATE

		@ HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC	

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

>D>	+	BRISTOL MYERS SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN	
>A>	+	WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN	

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

	+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA	

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP		AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA	
AP		GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA	

MESNEX

AP	+	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG	

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

AN		NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA	
AN			0.6%	N75403 001	FEB 28, 2001	FEB	NEWA	

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

		@ APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	MAY	DISC	
		@	50MG	N40011 002	JUL 17, 1997	MAY	DISC	

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB		EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA	
AB			10MG	N40411 002	MAR 27, 2001	MAR	NEWA	
>A>	+	GENPHARM	20MG	N40350 003	JUN 07, 2001	JUN	NEWA	

METHOTREXATE SODIUM

TABLET; ORAL

TREXALL

		BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA	
			EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA	
			EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA	

+		EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA
METHSCOPOLAMINE BROMIDE						
TABLET; ORAL						
METHSCOPOLAMINE BROMIDE						
@ PVT FORM		2.5MG	N80970 001	OCT 18, 1976	MAY	DISC
PAMINE						
+ BRADLEY PHARMS		2.5MG	N08848 001	APR 09, 1953	MAY	CTEC
METHYLDOPA						
TABLET; ORAL						
METHYLDOPA						
@ LEDERLE		125MG	N70070 003	OCT 15, 1985	MAY	DISC
METHYLPHENIDATE HYDROCHLORIDE						
CAPSULE, EXTENDED RELEASE; ORAL						
METADATE CD						
+ CELLTECH PHARMS		20MG	N21259 001	APR 03, 2001	APR	NEWA
TABLET; ORAL						
METHYLPHENIDATE HCL						
AB ABLE		5MG	N40404 001	MAR 29, 2001	MAR	NEWA
AB		10MG	N40404 002	MAR 29, 2001	MAR	NEWA
AB		20MG	N40404 003	MAR 29, 2001	MAR	NEWA
TABLET, EXTENDED RELEASE; ORAL						
METADATE ER						
AB CELLTECH PHARMS		10MG	N40306 001	OCT 20, 1999	APR	CTEC
METHYLPHENIDATE HCL						
AB ABLE		20MG	N76032 001	MAY 09, 2001	MAY	NEWA
AB DANBURY PHARMA		20MG	N40410 001	FEB 09, 2001	FEB	NEWA
METHYLPREDNISOLONE ACETATE						
INJECTABLE; INJECTION						
DEPO-MEDROL						
PHARMACIA AND UPJOHN		40MG/ML	N11757 001	APR 27, 1959	MAY	CTEC
METHYLPREDNISOLONE ACETATE						
@ STERIS		40MG/ML	N85600 001	MAR 14, 1979	MAY	DISC
METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE						
CREAM; TOPICAL						
NEO-MEDROL ACETATE						
@ PHARMACIA AND UPJOHN		0.25%;EQ 3.5MG BASE/GM	N60611 002	DEC 07, 1964	MAY	DISC
@		1%;EQ 3.5MG BASE/GM	N60611 001	DEC 07, 1964	MAY	DISC
METHYLPREDNISOLONE SODIUM SUCCINATE						
INJECTABLE; INJECTION						
METHYLPREDNISOLONE SODIUM SUCCINATE						
@ GENSIA SICOR PHARMS		EQ 500MG BASE/VIAL	N81267 001	NOV 30, 1992	MAY	DISC
@		EQ 1GM BASE/VIAL	N81268 001	NOV 30, 1992	MAY	DISC
METHYLTESTOSTERONE						
TABLET; BUCCAL						
ORETON						
@ SCHERING		10MG	N80281 001	AUG 03, 1979	FEB	DISC

	METOCLOPRAMIDE HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	METOCLOPRAMIDE HCL					
	@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC
	SOLUTION; INJECTION					
	METOCLOPRAMIDE					
AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA
	SOLUTION; ORAL					
AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR
	TABLET; ORAL					
	METOCLOPRAMIDE HCL					
AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN
	METOPROLOL SUCCINATE					
	TABLET, EXTENDED RELEASE; ORAL					
	TOPROL-XL					
	+ ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA
	METRONIDAZOLE					
	INJECTABLE; INJECTION					
	METRO I.V.					
	@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC
	METRONIDAZOLE					
	@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC
	@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC
	TABLET; ORAL					
	PROTOSTAT®					
	@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC
	@	500MG	N18871 002	MAR 02, 1983	MAR	DISC
	MEZLOCILLIN SODIUM MONOHYDRATE					
	INJECTABLE; INJECTION					
	MEZLIN					
	@ BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC
	@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC
	@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC
	@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC
	MIDAZOLAM HYDROCHLORIDE					
	INJECTABLE; INJECTION					
	MIDAZOLAM HCL					
	@ APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC
	@	EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC
	@	EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC
	@ ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC
	MINOCYCLINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	MINOCIN					
AB	LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA

AB	+		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD	
	MINOCYCLINE HCL							
AB		DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD	
AB		IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA	
	VECTRIN							
	@	MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC	
	@		EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC	
	POWDER, EXTENDED RELEASE; DENTAL							
	ARESTIN							
	+	ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA	
	MIRTAZAPINE							
	TABLET, ORALLY DISINTEGRATING; ORAL							
	REMERON SOLTAB							
	+	ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA	
			30MG	N21208 002	JAN 12, 2001	JAN	NEWA	
			45MG	N21208 003	JAN 12, 2001	JAN	NEWA	
	MORPHINE SULFATE							
	CAPSULE, EXTENDED RELEASE; ORAL							
	KADIAN							>D>
>D>	+	FAULDING	20MG	N20616 001	JUL 03, 1996	JUN	CAHN	>A>
>D>	+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN	>D>
>D>	+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN	>A>
>A>	+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN	
>A>	+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA	
>A>	+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN	
>A>	+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA	
>A>	+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN	
	TABLET, EXTENDED RELEASE; ORAL							
	MORPHINE SULFATE							
AB		WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA	
	NADOLOL							
	TABLET; ORAL							
	NADOLOL							
AB		GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN	
AB			40MG	N74501 002	NOV 09, 1995	JAN	CAHN	
AB			80MG	N74501 003	NOV 09, 1995	JAN	CAHN	
	NAFCILLIN SODIUM							
	INJECTABLE; INJECTION							
	NAFCILLIN SODIUM							
	@	APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC	
	+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD	
	@		EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC	
	@		EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC	
	@		EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC	
	@	MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC	
	@		EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN	
	@		EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC	
	@		EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC	
	@		EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC	

	@	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC	
	NALLPEN						
	@ SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001	JUL 10, 1978	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N61999 002	JUL 10, 1978	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N61999 003	JUL 10, 1978	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N61999 004	JUL 17, 1978	MAY	DISC	
	UNIPEN						
	@ WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	JUN 23, 1970	MAY	DISC	
	@	EQ 500MG BASE/VIAL	N62717 001	DEC 16, 1986	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62717 002	DEC 16, 1986	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N50320 003	JUN 23, 1970	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62717 004	DEC 16, 1986	MAY	DISC	
	@	EQ 4GM BASE/VIAL	N50320 004	JUN 23, 1970	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N50320 005	DEC 21, 1978	MAY	DISC	
	UNIPEN IN PLASTIC CONTAINER						
	@ WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	JUN 23, 1970	MAY	DISC	
NALBUPHINE HYDROCHLORIDE							
INJECTABLE; INJECTION							
	NALBUPHINE HCL						
>D> AP	ASTRAZENECA	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC	
>A>	@	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC	
>D> AP		20MG/ML	N72073 001	APR 10, 1989	JUN	DISC	
>A>	@	20MG/ML	N72073 001	APR 10, 1989	JUN	DISC	
NALOXONE HYDROCHLORIDE							
INJECTABLE; INJECTION							
	NALOXONE						
	@ WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC	
	@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC	
	@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC	
	@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC	
NAPHAZOLINE HYDROCHLORIDE							
SOLUTION/DROPS; OPHTHALMIC							
	VASOCON						
AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN	
NAPROXEN							
TABLET, EXTENDED RELEASE; ORAL							
	NAPROXEN						
AB +	ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA	
AB +		500MG	N75390 002	APR 19, 2001	APR	NEWA	
NAPROXEN SODIUM							
TABLET; ORAL							
	NAPROXEN SODIUM						
AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN	
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN	

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE
BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994 APR CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES
@ STERIS EQ 40MG BASE/ML;200,000 UNITS/ML N62664 001 APR 08, 1986 MAY DISC
NEOSPORIN G.U. IRRIGANT
MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML N60707 001 JUN 28, 1966 MAY CTEC

NETILMICIN SULFATE
INJECTABLE; INJECTION
NETROMYCIN
@ SCHERING EQ 100MG BASE/ML N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE
@ CHASE LABS NJ 10MG N72409 001 JUL 04, 1990 FEB WDRP
@ 20MG N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB1 BAYER 30MG N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE
AB2 BIOVAIL 30MG N75289 002 FEB 06, 2001 FEB NEWA
PROCARDIA XL
AB2 +' PFIZER 30MG N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE
OINTMENT; TOPICAL
NITROFURAZONE
@ CLAY PARK 0.2% N84968 001 JAN 25, 1978 MAY DISC
POWDER; TOPICAL
FURACIN
@ ROBERTS LABS 0.2% N83791 001 OCT 17, 1975 FEB WDRP
SOLUTION; TOPICAL
NITROFURAZONE
@ CLAY PARK 0.2% N85130 001 NOV 02, 1978 MAY DISC
+ WENDT 0.2% N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL
@ POHL BOSKAMP 0.4MG/SPRAY N18705 001 OCT 31, 1985 APR DISC

NORETHINDRONE ACETATE
TABLET; ORAL
NORETHINDRONE ACETATE

	AB	BARR	5MG	N75951 001	MAY 25, 2001	MAY	NEWA

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE; ORAL
PAMELOR

>D>	AB	NOVARTIS	EQ 10MG BASE	N18013 001	AUG 01, 1977	JUN	CAHN
>D>	AB		EQ 25MG BASE	N18013 002	AUG 01, 1977	JUN	CAHN
>D>	AB		EQ 50MG BASE	N18013 004	JUN 14, 1979	JUN	CAHN
>D>	AB +		EQ 75MG BASE	N18013 003	JUN 14, 1979	JUN	CAHN
>A>	AB	TYCO HLTHCARE	EQ 10MG BASE	N18013 001	AUG 01, 1977	JUN	CAHN
>A>	AB		EQ 25MG BASE	N18013 002	AUG 01, 1977	JUN	CAHN
>A>	AB		EQ 50MG BASE	N18013 004	JUN 14, 1979	JUN	CAHN
>A>	AB +		EQ 75MG BASE	N18013 003	JUN 14, 1979	JUN	CAHN

SOLUTION; ORAL

>D>	AA	NOVARTIS	EQ 10MG BASE/5ML	N18012 001	AUG 01, 1977	JUN	CAHN
>A>	AA	TYCO HLTHCARE	EQ 10MG BASE/5ML	N18012 001	AUG 01, 1977	JUN	CAHN

NYSTATIN
CREAM; TOPICAL
NILSTAT

		@ LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY	DISC

NYSTATIN

		@ TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY	DISC

OINTMENT; TOPICAL
NILSTAT

		@ LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY	DISC

NYSTATIN

	AT +	ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY	CTEC

SUSPENSION; ORAL

		@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY	DISC
		@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY	DISC
		@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY	DISC

TABLET; ORAL

		@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC
		@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC

TABLET; VAGINAL
KOROSTATIN

		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP

NYSTATIN; TRIAMCINOLONE ACETONIDE
OINTMENT; TOPICAL
MYCO-TRIACET II

		@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC

NYSTATIN AND TRIAMCINOLONE ACETONIDE

		@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC

		OLANZAPINE						
		TABLET; ORAL						
		ZYPREXA						
>D>	+	LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD	
>A>			15MG	N20592 005	SEP 09, 1997	JUN	CRLD	
>D>		@	20MG	N20592 006	SEP 09, 1997	JUN	CMFD	
>A>	+		20MG	N20592 006	SEP 09, 1997	JUN	CMFD	
		OXACILLIN SODIUM						
		INJECTABLE; INJECTION						
		BACTOCILL						
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC	
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC	
		OXACILLIN SODIUM						
AP	+	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD	
AP	+		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD	
		@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC	
		@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC	
		@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC	
		@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC	
		@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC	
		OXAPROZIN						
		TABLET; ORAL						
		DAYPRO						
AB	+	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG	
		OXAPROZIN						
AB		DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA	
AB		EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA	
AB		GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA	
AB		GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA	
AB		INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA	
AB		WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA	
		OXAZEPAM						
		CAPSULE; ORAL						
		SERAX						
>D>	AB	FAULDING	10MG	N15539 002	SEP 29, 1966	JUN	CAHN	
>D>	AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN	
>D>	AB	+	30MG	N15539 006	SEP 29, 1966	JUN	CAHN	
>A>	AB	FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN	
>A>	AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN	
>A>	AB	+	30MG	N15539 006	SEP 29, 1966	JUN	CAHN	
		TABLET; ORAL						
>D>	+	FAULDING	15MG	N15539 008	NOV 16, 1967	JUN	CAHN	
>A>	+	FAULDING PHARMS	15MG	N15539 008	NOV 16, 1967	JUN	CAHN	
		OXCARBAZEPINE						
		SUSPENSION; ORAL						
		TRILEPTAL						
	+	NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA	

OXYCODONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

>D>	+	PURDUE PHARMA LP	160MG	N20553 005	MAR 15, 2000	JUN	DISC
>A>		@	160MG	N20553 005	MAR 15, 2000	JUN	DISC

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
OXYTETRACYCLINE HCL

		@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
		@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
		@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC

TERRAMYCIN

	+	PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL

AP		ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
AREDIA

AP	+	NOVARTIS	30MG/VIAL	N20036 001	OCT 31, 1991	APR	CFTG
AP	+		90MG/VIAL	N20036 004	MAY 06, 1993	APR	CFTG

PAMIDRONATE DISODIUM

AP		BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP			90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV

	+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA

TABLET, DELAYED RELEASE; ORAL
PROTONIX

>A>	+	WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA

PEMOLINE
TABLET; ORAL
PEMOLINE

AB		MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB			37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB			75MG	N75726 001	MAR 30, 2001	MAR	NEWA
>A> AB		WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA

PENICILLIN G POTASSIUM
TABLET; ORAL
PENICILLIN G POTASSIUM

		@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC
		@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC
		@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC
		@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC

PENICILLIN G PROCAINE
INJECTABLE; INJECTION
PENICILLIN G PROCAINE
@ PFIZER 300,000 UNITS/VIAL N60099 001 NOV 10, 1948 MAY DISC
@ 1,500,000 UNITS/VIAL N60099 002 NOV 10, 1948 MAY DISC
PFIZERPEN-AS
@ PFIZER 300,000 UNITS/ML N60286 001 NOV 01, 1950 MAY DISC
@ 600,000 UNITS/ML N60286 002 NOV 01, 1950 MAY DISC
WYCILLIN
+ KING PHARMS 300,000 UNITS/ML N60101 002 APR 26, 1948 MAY CTEC
+ 600,000 UNITS/ML N60101 001 APR 26, 1948 MAY CTEC

PENICILLIN G SODIUM
INJECTABLE; IM-IV
PENICILLIN G SODIUM
+ BIOCHEMIE 5,000,000 UNITS/VIAL N65068 001 FEB 26, 2001 FEB NEWA
@ MARSAM 5,000,000 UNITS/VIAL N63014 001 SEP 13, 1988 FEB DISC

PENICILLIN V POTASSIUM
FOR SOLUTION; ORAL
PENICILLIN V POTASSIUM
@ MYLAN EQ 125MG BASE/5ML N61624 002 AUG 07, 1972 MAY DISC
@ EQ 250MG BASE/5ML N61624 001 JUN 05, 1972 MAY DISC
V-CILLIN K
@ LILLY EQ 125MG BASE/5ML N60004 001 AUG 21, 1958 MAY DISC
@ EQ 250MG BASE/5ML N60004 002 APR 07, 1967 MAY DISC
TABLET; ORAL
PEN-VEE K
AB + WYETH AYERST EQ 500MG BASE N60006 003 JAN 13, 1958 MAY CRLD
PENICILLIN V POTASSIUM
AB + BIOCHEMIE EQ 500MG BASE N64071 002 NOV 30, 1995 MAY CTEC
@ MYLAN EQ 250MG BASE N61530 001 NOV 18, 1971 MAY DISC
@ EQ 500MG BASE N61530 002 MAR 20, 1972 MAY DISC
V-CILLIN K
@ LILLY EQ 125MG BASE N60003 001 SEP 17, 1957 MAY DISC
@ EQ 250MG BASE N60003 002 SEP 17, 1957 MAY DISC
@ EQ 500MG BASE N60003 003 SEP 17, 1957 MAY DISC

PERPHENAZINE
CONCENTRATE; ORAL
PERPHENAZINE
+ PHARM ASSOC 16MG/5ML N40360 001 MAY 25, 2001 MAY NEWA
TRILAFON
@ SCHERING 16MG/5ML N11557 001 DEC 12, 1958 MAR DISC

>A> PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM
>A> TABLET, TABLET; ORAL
>A> SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL
>A> + ABLE 200MG,800MG;160MG N21105 001 JUN 26, 2001 JUN NEWA

PHENDIMETRAZINE TARTRATE
CAPSULE; ORAL
PHENDIMETRAZINE TARTRATE
@ EON 35MG N85694 001 JUN 05, 1978 MAY DISC
TABLET; ORAL
PHENAZINE-35
@ ABC HOLDING 35MG N85512 001 MAY 06, 1977 MAY DISC
PHENDIMETRAZINE TARTRATE
@ EON 35MG N85402 001 MAY 19, 1978 MAY DISC
@ 35MG N85497 001 AUG 19, 1977 MAY DISC
@ ROSEMONT 35MG N84399 001 MAY 28, 1981 MAY DISC

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
PHENTERMINE HCL
@ ABC HOLDING 30MG N85411 001 SEP 10, 1980 MAY DISC
@ ROSEMONT 30MG N84487 001 APR 09, 1982 MAY DISC
TABLET; ORAL
\+ EON 30MG N88605 001 SEP 28, 1987 MAY CMFD

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN
AB UDL 125MG/5ML N40342 001 JAN 31, 2001 JAN NEWA

PIPERAZINE CITRATE
SYRUP; ORAL
PIPERAZINE CITRATE
@ LANNETT EQ 500MG BASE/5ML N80963 001 JUL 25, 1974 MAY DISC
TABLET; ORAL
@ IMPAX LABS EQ 250MG BASE N80874 001 JUL 19, 1973 MAY DISC

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
K-DUR 10
AB KEY PHARMS 10MEQ N19439 002 JUN 13, 1986 APR CTEC

PREDNICARBATE
OINTMENT; TOPICAL
DERMATOP
\+ AVENTIS PHARMS 0.1% N19568 001 SEP 23, 1991 MAR CMFD

PREDNISOLONE
TABLET; ORAL
PREDNISOLONE
@ CHELSEA LABS 5MG N85085 002 FEB 23, 1977 MAY DISC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN
AT NOVARTIS 0.5%;10% N88791 001 OCT 05, 1984 FEB CAHN
SUSPENSION/DROPS; OPHTHALMIC

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
SUSPENSION/DROPS; OPHTHALMIC

		METIMYD					
	+	SCHERING	0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC
		PREDAMIDE					
		@ AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP
		SULPHRIN					
		@ BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION/DROPS; OPHTHALMIC

		INFLAMASE FORTE					
AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751 002	DEC 19, 1973	FEB	CAHN
		INFLAMASE MILD					
AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751 001	DEC 19, 1973	FEB	CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
		@ AKORN	EQ 0.11% PHOSPHATE	N83358 001	AUG 21, 1974	FEB	WDRP
		@	EQ 0.9% PHOSPHATE	N83358 002	AUG 21, 1974	FEB	WDRP
		@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991	MAY	DISC
		@	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991	MAY	DISC

PREDNISONE
TABLET; ORAL

		PREDNISONE					
		@ CHELSEA LABS	5MG	N85084 002	DEC 15, 1981	MAY	DISC
		@ GENEVA PHARMS	5MG	N80336 002	JUL 29, 1976	MAY	DISC
		@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC

PRIMIDONE
TABLET; ORAL

		MYSOLINE					
AB		ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
		PRIMIDONE					
AB		LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE MALEATE
TABLET; ORAL

		PROCHLORPERAZINE MALEATE					
AB		GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
AB			EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
AB			EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE
INJECTABLE; INJECTION

		PROGESTERONE					
AO		AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
AO	+	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL

		PROMETHACON					
		@ POLYMEDICA	50MG	N84902 001	OCT 05, 1981	MAY	DISC

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE
TABLET; ORAL
PHENERGAN
WYETH AYERST 12.5MG N07935 002 MAR 29, 1951 MAY CTEC
PROMETHAZINE HCL
@ LANNETT 12.5MG N80949 001 JUL 28, 1976 MAY DISC
@ 25MG N80949 002 JUN 28, 1976 MAY DISC
@ 50MG N80949 003 JUN 28, 1976 MAY DISC
@ PVT FORM 25MG N83658 001 OCT 01, 1976 MAY DISC

PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE HCL
@ GENEVA PHARMS 65MG N83125 002 APR 14, 1976 MAY DISC
@ IMPAX LABS 65MG N83317 001 OCT 23, 1973 MAY DISC

PROPRANOLOL HYDROCHLORIDE
TABLET; ORAL
PROPRANOLOL HCL
@ LEDERLE 10MG N70125 001 JUL 30, 1985 MAY DISC
@ WATSON LABS 20MG N70549 001 APR 11, 1986 MAY DISC

PROTRIPTYLINE HYDROCHLORIDE
TABLET; ORAL
PROTRIPTYLINE HCL
AB ODYSSEY PHARMS 5MG N73644 001 AUG 24, 1995 JAN CAHN
AB 10MG N73645 001 AUG 24, 1995 JAN CAHN
VIVACTIL
AB ODYSSEY PHARMS 5MG N73644 001 AUG 24, 1995 MAR CTNA
AB + 10MG N73645 001 AUG 24, 1995 MAR CTNA
@ SIDMAK LABS 5MG N16012 001 SEP 27, 1967 MAR DISC
@ 10MG N16012 002 SEP 27, 1967 MAR DISC

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE
SYRUP; ORAL
TRILITRON
@ NEWTRON PHARMS 30MG/5ML;1.25MG/5ML N88474 001 FEB 12, 1985 FEB WDRP

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE; ORAL
QUINAGLUTE
BX + BERLEX LABS 324MG N16647 001 DEC 08, 1969 MAR CTEC
QUINIDINE GLUCONATE
BX DANBURY PHARMA 324MG N87810 001 SEP 29, 1982 MAR CTEC
@ GENEVA PHARMS 324MG N89894 001 DEC 15, 1988 MAR DISC
BX MUTUAL PHARM 324MG N89338 001 FEB 11, 1987 MAR CTEC

QUINIDINE SULFATE
TABLET; ORAL
QUINIDINE SULFATE
@ IMPAX LABS 200MG N83347 001 DEC 08, 1976 FEB DISC
@ MUTUAL PHARM 300MG N81031 001 APR 14, 1989 MAY DISC
@ WEST WARD 200MG N83862 001 SEP 02, 1976 MAY DISC

	RIFAMPIN						
	CAPSULE; ORAL						
	RIFAMPIN						
AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA
	RISPERIDONE						
	TABLET; ORAL						
	RISPERDAL						
	JANSSEN	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
	+	1MG	N20272 001	DEC 29, 1993	APR	CRLD
		4MG	N20272 004	DEC 29, 1993	APR	CRLD
	SECOBARBITAL SODIUM						
	CAPSULE; ORAL						
	SECOBARBITAL SODIUM						
	@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP
	SECRETIN						
>D>	INJECTABLE; INJECTION						
>D>	SECRETIN-FERRING						
>D>	+ FERRING	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC
>A>	@	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC
	SILVER SULFADIAZINE						
	DRESSING; TOPICAL						
	SILDAFLO						
	@ QUESTCOR PHARMS	1%	N19608 001	NOV 30, 1989	MAY	CTNA
	SIMVASTATIN						
	TABLET; ORAL						
	ZOCOR						
	MERCK	5MG	N19766 001	DEC 23, 1991	APR	CTEC
	SODIUM POLYSTYRENE SULFONATE						
	SUSPENSION; ORAL, RECTAL						
	SPS						
AA	+ CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD
	SOTALOL HYDROCHLORIDE						
	TABLET; ORAL						
	SORINE						
AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
AB		240MG	N75500 003	APR 27, 2001	APR	NEWA
	STREPTOMYCIN SULFATE						
	INJECTABLE; INJECTION						
	STREPTOMYCIN SULFATE						
	@ PFIZER	EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
	@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC

+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10					
@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC
CETAMIDE					
AT + ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC
SODIUM SULAMYD					
@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10					
AT + ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD
BLEPH-30					
AT + ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD
SODIUM SULAMYD					
@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC
@	30%	N05963 003	NOV 26, 1947	MAY	DISC
SULF-10					
@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN
SULF-15					
AT NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN
SULTEN-10					
@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP

SULFAMETHOXAZOLE

TABLET; ORAL

GANTANOL					
+ ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC
SULFAMETHOXAZOLE					
@ GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA					
@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP

TABLET; ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

@ TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC
@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC

SULFANILAMIDE

CREAM; VAGINAL

AVC					
AT + NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN

SUPPOSITORY; VAGINAL

+ NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION

ACUTECT					
BERLEX LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN
DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	APR	CAHN

TEMAZEPAM
CAPSULE; ORAL
RESTORIL

>D>		NOVARTIS	7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN
>D>	AB		15MG	N18163 001	FEB 27, 1981	JUN	CAHN
>D>	AB +		30MG	N18163 002	FEB 27, 1981	JUN	CAHN
>A>		TYCO HLTHCARE	7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN
>A>	AB		15MG	N18163 001	FEB 27, 1981	JUN	CAHN
>A>	AB +		30MG	N18163 002	FEB 27, 1981	JUN	CAHN

TERAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
TERAZOSIN HCL

	AB	TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
	AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA
	AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
	AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
	AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
	AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
	AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA

TERBUTALINE SULFATE
TABLET; ORAL
BRETHINE

>D>		NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
>A>	AB		2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
>D>	+		5MG	N17849 002	MAY 17, 1976	JUN	CFTG
>A>	AB +		5MG	N17849 002	MAY 17, 1976	JUN	CFTG
>A>		TERBUTALINE SULFATE					
>A>	AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
>A>	AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
PANMYCIN

		@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC
		ROBITET					
		@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
		@	500MG	N61734 002	JUN 06, 1973	MAY	DISC
		TETRACYCLINE HCL					
		@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
		@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
		@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
		@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC
		@	500MG	N60768 002	NOV 07, 1977	MAY	DISC

THIOTEPA
INJECTABLE; INJECTION
THIOPLEX

AP	+	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
		THIOTEPA					

THIOTEPA
INJECTABLE; INJECTION
THIOTEPA

	AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
JUN CAHN	AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
JUN CAHN	+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
JUN CAHN	@	IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC
JUN CAHN							
JUN CAHN							
JUN CAHN							

THYROGLOBULIN
TABLET; ORAL
THYROGLOBULIN

	@	IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC

TICARCILLIN DISODIUM
INJECTABLE; INJECTION
TICAR

APR NEWA	@	SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC
APR NEWA							
APR NEWA							
APR NEWA							
JAN NEWA							
JAN NEWA							
JAN NEWA							
JAN NEWA							

TOBRAMYCIN
SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

	@	ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC

TOBRAMYCIN SULFATE
INJECTABLE; INJECTION
TOBRAMYCIN SULFATE

JUN CFTG	@	ASTRAZENECA	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
JUN CFTG	@	ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
JUN CFTG	@		EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
JUN CFTG	@	LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC

TOPIRAMATE
TABLET; ORAL
TOPAMAX

JUN NEWA	+	JOHNSON RW	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
JUN NEWA			200MG	N20505 002	DEC 24, 1996	MAR	CRLD

TRAVOPROST
SOLUTION/DROPS; OPHTHALMIC
TRAVATAN

MAY DISC	+	ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA
MAY DISC							
MAY DISC							

TRIAMCINOLONE
TABLET; ORAL
TRIAMCINOLONE

MAY DISC	@	IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC
MAY DISC							
MAY DISC							
MAY DISC							
MAY DISC							

TRIAMCINOLONE ACETONIDE
CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

	@	TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC
APR CFTG	@	TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
	@		0.1%	N89275 001	FEB 21, 1989	FEB	WDRP

		@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
		OINTMENT; TOPICAL					
>A>	AT	THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA
>A>	AT		0.5%	N40386 001	JUN 05, 2001	JUN	NEWA
		TRICHLORMETHIAZIDE					
		TABLET; ORAL					
		TRICHLOREX					
		@ LANNETT	4MG	N83436 001	AUG 11, 1980	MAY	DISC
		@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP
		TRIFLUOPERAZINE HYDROCHLORIDE					
		CONCENTRATE; ORAL					
		TRIFLUOPERAZINE HCL					
		@ GENEVA PHARMS	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC
		TABLET; ORAL					
	AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN
	AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN
	AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN
	AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN
		TRIMETHOPRIM HYDROCHLORIDE					
		SOLUTION; ORAL					
		PRIMSOL					
>D>		+ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC
>A>		@	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC
		TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)					
		CREAM; VAGINAL					
		TRIPLE SULFA					
>D>	AT	FOUGERA	3.7%;2.86%;3.42%	N86424 001	MAY 31, 1979	JUN	DISC
>A>		@	3.7%;2.86%;3.42%	N86424 001	MAY 31, 1979	JUN	DISC
		TRIPTORELIN PAMOATE					
		INJECTABLE; INTRAMUSCULAR					
>A>		TRELSTAR					
>A>		+ DEBIO RECHERCHE	11.25MG/VIAL	N21288 001	JUN 29, 2001	JUN	NEWA
>A>		TRELSTAR DEPOT					
>D>		+ DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	JUN	CDFR
>A>		+	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	JUN	CDFR
		URACIL MUSTARD					
>D>		CAPSULE; ORAL					
>D>		URACIL MUSTARD					
>D>		+ ROBERTS LABS	1MG	N12892 001	SEP 13, 1962	JUN	DISC
>A>		@ SHIRE PHARM	1MG	N12892 001	SEP 13, 1962	JUN	DISC
		VALGANCICLOVIR HYDROCHLORIDE					
		TABLET; ORAL					
		VALCYTE					
		+ SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001	MAR	NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID
@ PAR PHARM 250MG N70431 001 FEB 28, 1986 MAY DISC

VANCOMYCIN HYDROCHLORIDE
INJECTABLE; INJECTION
VANCOMYCIN HCL
@ ELKINS SINN EQ 500MG BASE/VIAL N62879 001 AUG 02, 1988 MAY DISC
@ EQ 1GM BASE/VIAL N62879 002 AUG 02, 1988 MAY DISC

VINBLASTINE SULFATE
INJECTABLE; INJECTION
VELBAN
@ LILLY 10MG/VIAL N12665 001 MAR 06, 1961 MAY DISC
VINBLASTINE SULFATE
AP + BEDFORD 10MG/VIAL N89395 001 APR 09, 1987 MAY CRLD

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A
@ WEST WARD EQ 50,000 UNITS BASE N80967 001 MAY 04, 1973 FEB WDRP

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON
PFIZER 20MG N20825 001 FEB 05, 2001 FEB NEWA
40MG N20825 002 FEB 05, 2001 FEB NEWA
60MG N20825 003 FEB 05, 2001 FEB NEWA
+ 80MG N20825 004 FEB 05, 2001 FEB NEWA

ZOLMITRIPTAN
TABLET, ORALLY DISINTEGRATING; ORAL
ZOMIG-ZMT
ASTRAZENECA 2.5MG N21231 001 FEB 13, 2001 FEB NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL
ACETAMINOPHEN
ALPHARMA US PHARM 120MG N18337 003 SEP 12, 1983 MAR CAHN
325MG N18337 002 AUG 21, 1981 MAR CAHN
\+ 650MG N18337 001 APR 22, 1980 MAR CAHN
INFANTS' FEVERALL
ALPHARMA US PHARM 80MG N18337 004 AUG 26, 1992 MAR CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
TAVIST ALLERGY/SINUS/HEADACHE
\+ NOVARTIS 500MG;EQ 0.25MG BASE;30MG N21082 001 MAR 01, 2001 MAR NEWA >A>

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL
>A> AVAGARD
>A> \+ 3M 61%;1% N21074 001 JUN 07, 2001 JUN NEWA

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TAVIST-D
@ NOVARTIS 1.34MG;75MG N18298 002 AUG 21, 1992 JAN DISC
@ 1.34MG;75MG N20640 001 AUG 09, 1996 JAN DISC

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE
TEVA 10MG N75312 001 MAY 31, 2001 MAY NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
IBUPROHM COLD AND SINUS
OHM LABS 200MG;30MG N74567 001 APR 17, 2001 APR NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN
\+ NOVO NORDISK 100 UNITS/ML N18381 001 MAR 17, 1980 MAY CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R
\+ NOVO NORDISK 100 UNITS/ML N19938 001 JUN 25, 1991 MAY CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50
\+ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 APR 29, 1992 MAY CTEC
NOVOLIN 70/30
\+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19991 001 JUN 25, 1991 MAY CTEC

MICONAZOLE NITRATE

CREAM; TOPICAL

MONISTAT 3 COMBINATION PACK

\+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 FEB NEWA

CREAM; TOPICAL, VAGINAL

\+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 MAY CDFR

CREAM; VAGINAL

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

>A> PERRIGO 5% N75598 001 JUN 13, 2001 JUN NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE '01

NO JUNE 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List

June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
9-nitro-20-(S)-camptothecin TN=Camvirex	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	The Brain Tumor Center at Duke Duke University Medical Center Room 047, Baker House, South Durham NC 27710 DD= 3/5/01 MA=

Orphan Products Designations and Approvals List
June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=
Glatiramer acetate for injection TN=Copaxone	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road North Wales PA 19454 DD= 6/5/01 MA=
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=
human gammaglobulin TN=	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
Imatinib TN=Gleevec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01

Orphan Products Designations and Approvals List
June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
INH-A00021 TN=	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway Suite 150 Alpharetta GA 30004 DD= 6/13/01 MA=
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Latrodectus immune F(ab)2 TN=Aracmyn	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 6/18/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
muramyltripeptide, phosphatidyl-ethanol amine encased in multi-lamellar liposomes TN=	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184 DD= 6/5/01 MA=

Orphan Products Designations and Approvals List
June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=

Orphan Products Designations and Approvals List
June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
Reviparin sodium TN=Clivarine	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
Reviparin sodium TN=Clivarine	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
squalamine lactate TN=	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Unconjugated Chimeric human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=

Orphan Products Designations and Approvals List
June 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
>ADD>	021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
						I-262	JUN 02, 2002
	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	021001 001	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021001 002	ALMOTRIPTAN MALATE;AXERT				NCE	MAY 07, 2006
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013		NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
	019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
			5962731	OCT 05, 2016			
			5466861	NOV 14, 2012			
	020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
			5712251	SEP 18, 2001	U-391		
	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P				NP	MAY 16, 2004
>ADD>	020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
>ADD>	020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
>ADD>	020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
>ADD>	020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
>ADD>	076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
>ADD>	020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
>ADD>	018874 001	CALCITRIOL;CALCIJEX	6265392	AUG 02, 2019			
			4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
>ADD>	018874 002	CALCITRIOL;CALCIJEX	6265392	AUG 02, 2019			
			4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
>ADD>	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	021005 001	DICLOFENAC SODIUM;SOLARAZE				NP	OCT 16, 2003
	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
	020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248		
			5254539	AUG 29, 2006	U-248		
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
>ADD>	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
>ADD>			5985864	DEC 30, 2016			
			6245911	DEC 01, 2018			
>ADD>	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
>ADD>			5985864	DEC 30, 2016			
			6245911	DEC 01, 2018			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
	021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4508905	FEB 20, 2001			
	021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
			4738974	APR 19, 2005	U-373		
			4636499	MAY 30, 2005	U-373		
			5900424	MAY 04, 2016	U-373		
			4786505	APR 20, 2007	U-373		
			4853230	APR 20, 2007	U-373		
			5714504	FEB 03, 2015	U-373		
			5877192	MAY 27, 2014	U-373		
			5093342	FEB 02, 2010	U-373		
			5599794	FEB 04, 2014	U-373		
			5629305	FEB 04, 2014	U-373		
			5690960	NOV 25, 2014	U-373		
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4508905	FEB 20, 2001			
>ADD>	020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
>ADD>	020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
>ADD>			5656286	AUG 12, 2014			
>ADD>			5958446	DEC 12, 2012			
>ADD>			6024976	JAN 07, 2014			
>ADD>	020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
>ADD>	020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
>ADD>	020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
>ADD>	020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
>ADD>			RE35524	AUG 04, 2007			
>ADD>	020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
>ADD>			RE35524	AUG 04, 2007			
>ADD>	075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
						PED	MAY 09, 2002
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
>ADD>	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017		NDF	FEB 26, 2004
>ADD>			5985322	MAY 29, 2017			
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			4886808	DEC 29, 2007	U-89		
>ADD>	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
>ADD>	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	5608075	MAR 04, 2014			
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR				NP	MAR 16, 2003
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI	6211246	JUN 10, 2019			
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO				NCE	MAY 10, 2006
	021335 002	IMATINIB MESYLATE;GLEEVEC				ODE	MAY 10, 2008
			5656722	SEP 12, 2014			
	021081 001	INSULIN GLARGINE;LANTUS				I-327	OCT 27, 2003
	020394 001	IPRATROPIUM BROMIDE;ATROVENT					
	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
						I-332	MAY 09, 2004
>ADD>	020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
>ADD>	020966 001	ITRACONAZOLE;SPORANOX	6180639	JAN 30, 2018	U-248		
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR				I-316	NOV 30, 2003
	021281 001	LANSOPRAZOLE;PREVACID				M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
>ADD>	020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
						PC	JAN 12, 2002
>ADD>	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				M-6	APR 19, 2004
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE					

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
			5514698	MAR 21, 2014			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
>ADD>	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
>ADD>			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	075269 001	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
>ADD>	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012			
>ADD>	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
>ADD>	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
>ADD>	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
>ADD>	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
>ADD>	020592 005	OLANZAPINE;ZYPREXA	6251985	SEP 23, 2017		NCE	SEP 30, 2001
			5229382	APR 23, 2011	U-149		
			5605897	FEB 25, 2014	U-176		
>ADD>	020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
			5952375	FEB 02, 2016		NCE	OCT 27, 2004
>ADD>	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115	MAY 22, 2015	U-393		
			6124355	MAY 22, 2015	U-378		
>ADD>	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115	MAY 22, 2015	U-393		
			6124355	MAY 22, 2015	U-378		
>ADD>	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115	MAY 22, 2015	U-393		
			6124355	MAY 22, 2015	U-378		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
			5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
>ADD>	020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
>ADD>	020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
>ADD>	020036 004	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-330	JUN 12, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
						NCE	FEB 02, 2005
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
>ADD>	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
>ADD>	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
>ADD>	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020903 001	RIBAVIRIN;REBETOL	6172046	SEP 21, 2017	U-377	PED	JUN 09, 2002
			5767097*PED	JUL 23, 2016	U-235	PED	DEC 03, 2001
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2017	U-375		
			6172046*PED	MAR 21, 2018	U-377		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020692 001	SALMETEROL XINAFOATE;SEREVENT	5290815	MAR 01, 2011	U-386		
>ADD>	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
>ADD>	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
>ADD>	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
>ADD>	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
>ADD>						M-9	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
>ADD>						M-9	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
>ADD>						M-9	FEB 16, 2004
>ADD>	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN				I-334	JUL 25, 2004
>ADD>	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				I-334	JUL 25, 2004
>ADD>	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
>ADD>	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
>ADD>	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
>ADD>	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
>ADD>	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
>ADD>	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				I-334	JUL 25, 2004
						NP	FEB 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
						NP	FEB 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
						NP	FEB 22, 2003
>ADD>	020412 001	STAVUDINE;ZERIT				PED	AUG 22, 2003
>ADD>			4978655	JUN 24, 2008	U-94		
>ADD>	020412 002	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
>ADD>			4978655	JUN 24, 2008	U-94		
>ADD>	020412 003	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
>ADD>			4978655	JUN 24, 2008	U-94		
>ADD>	020412 004	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008			
>ADD>			4978655	JUN 24, 2008	U-94		
>ADD>	020412 005	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
>ADD>			4978655	JUN 24, 2008	U-94		
>ADD>	020898 001	THYROTROPIN ALFA;THYROGEN	4978655*PED	DEC 24, 2008	U-94		
>ADD>			5674711	AUG 31, 2010			
>ADD>			5602006	FEB 11, 2014			
>ADD>			5658760	AUG 19, 2014			
>ADD>			5240832	AUG 31, 2010			
>ADD>			6114144	NOV 24, 2015			
>ADD>			5840566	NOV 24, 2015			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
>ADD>	020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
>ADD>	020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
>ADD>	020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
>ADD>	020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
>ADD>	020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
>ADD>	020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
>ADD>	020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		
	019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
			4603146	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
>ADD>	021288 001	TRIPTORELIN PAMOATE;TRELSTAR				NP	JUN 29, 2004
>ADD>						NCE	JUN 15, 2005
>ADD>	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
>ADD>	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
>ADD>	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
>ADD>	021283 001	VALSARTAN;DIOVAN				NCE	DEC 23, 2001
>ADD>	021283 002	VALSARTAN;DIOVAN				NCE	DEC 23, 2001
>ADD>	021283 003	VALSARTAN;DIOVAN				NCE	DEC 23, 2001
	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR				I-325	MAY 02, 2004
	020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
	020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
	020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
>ADD>	021223 001	ZOLEDRONIC ACID;ZOMETA				NCE	AUG 20, 2006
	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE

PATENT AND EXCLUSIVITY TERMS

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

PATENT USE CODE

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT

*U.S. Government Printing Office: 2001 — 472-432/40001

New 21st Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/00)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.